Publications
Detailed Information
Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Sung Hee | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Kim, Jae-Joon | - |
dc.contributor.author | Im, Hyeon-Su | - |
dc.contributor.author | Kim, In-Ho | - |
dc.contributor.author | Han, Hye Sook | - |
dc.contributor.author | Koo, Dong-Hoe | - |
dc.contributor.author | Cho, Jang Ho | - |
dc.contributor.author | Maeng, Chi Hoon | - |
dc.contributor.author | Lee, Min-Young | - |
dc.contributor.author | Lee, Hyo Jin | - |
dc.contributor.author | Kim, Jwa Hoon | - |
dc.contributor.author | Park, Sang Gon | - |
dc.contributor.author | Jung, Joo Young | - |
dc.contributor.author | Shin, Seong-Hoon | - |
dc.contributor.author | Kim, Ki Hyang | - |
dc.contributor.author | Kim, Hyeyeong | - |
dc.contributor.author | Oh, So Yeon | - |
dc.contributor.author | Kang, Minsu | - |
dc.contributor.author | Jung, Minkyu | - |
dc.contributor.author | Rha, Sun Young | - |
dc.date.accessioned | 2024-03-04T05:39:05Z | - |
dc.date.available | 2024-03-04T14:40:09Z | - |
dc.date.issued | 2024-02-23 | - |
dc.identifier.citation | BMC Cancer, Vol.24 no.252 | ko_KR |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.uri | https://hdl.handle.net/10371/199042 | - |
dc.description.abstract | Background
Immune checkpoint inhibitor (ICI) or irinotecan-based chemotherapy is frequently used after failure of second-line paclitaxel plus ramucirumab treatment for patients with locally advanced unresectable or metastatic advanced gastric cancer (AGC). This study aimed to compare the efficacy between ICI and irinotecan-based chemotherapy as third-line treatment in patients with AGC. Methods We retrospectively reviewed patients with AGC, whose third-line treatment started between July 2019 and June 2021 at 17 institutions in Korea. The ICI group included patients who received nivolumab or pembrolizumab, and the irinotecan-based chemotherapy group included patients who received irinotecan or FOLFIRI (5-fluorouracil, leucovorin and irinotecan). Results A total of 363 patients [n = 129 (ICI) and n = 234 (irinotecan-based chemotherapy)] were analyzed. The median progression-free survival was 2.3 and 2.9 months in ICI and irinotecan-based chemotherapy groups, respectively (p = 0.802). The median overall survival (OS) was 5.5 and 6.0 months in ICI and irinotecan-based chemotherapy groups, respectively (p = 0.786). For all patients included in this study, multivariable analysis showed that weight loss, peritoneal metastasis, low serum sodium or albumin, and short duration of second-line treatment were associated with inferior OS (p < 0.05). ICI showed significantly longer OS than irinotecan-based chemotherapy in patients without peritoneal metastasis. Whereas ICI showed significantly shorter OS in patients without PD-L1 expression than irinotecan-based chemotherapy. Conclusions No significant difference in survival outcome was observed between ICI and irinotecan-based chemotherapy as third-line treatment for AGC patients. ICI might be preferred for patients without peritoneal metastasis and irinotecan-based chemotherapy for patients with tumors without PD-L1 expression. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BMC | ko_KR |
dc.subject | Gastric cancer | - |
dc.subject | Third-line treatment | - |
dc.subject | Irinotecan | - |
dc.subject | Nivolumab | - |
dc.subject | Pembrolizumab | - |
dc.title | Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06) | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1186/s12885-024-11972-w | ko_KR |
dc.citation.journaltitle | BMC Cancer | ko_KR |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s) | - |
dc.date.updated | 2024-02-25T04:13:33Z | - |
dc.citation.number | 252 | ko_KR |
dc.citation.volume | 24 | ko_KR |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.